Shiho Nagata

Baloxavir susceptibility of seasonal influenza viruses during the first seven seasons of clinical use in Japan, 2017/18 to 2023/24.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: January 09, 2026

Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024.

Journal: Emerging infectious diseases

Published: April 03, 2025

Impact of the polymerase acidic protein E199K substitution in influenza A viruses on baloxavir susceptibility.

Journal: Antiviral research

Published: February 25, 2025

An outbreak of influenza A(H1N1)pdm09 antigenic variants exhibiting cross-resistance to oseltamivir and peramivir in an elementary school in Japan, September 2024.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: December 13, 2024

Impact of COVID-19 on Respiratory Virus Infections in Children, Japan, 2018-2023.

Journal: Immunity, inflammation and disease

Published: September 15, 2024

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: May 15, 2024

Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023.

Journal: Influenza and other respiratory viruses

Published: February 13, 2024

A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: September 28, 2023

Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.

Journal: Antiviral research

Published: April 03, 2023

Baloxavir susceptibility of seasonal influenza viruses during the first seven seasons of clinical use in Japan, 2017/18 to 2023/24.

Baloxavir susceptibility of seasonal influenza viruses during the first seven seasons of clinical use in Japan, 2017/18 to 2023/24.

Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024.

Influenza A(H1N1)pdm09 Virus with Reduced Susceptibility to Baloxavir, Japan, 2024.

Impact of the polymerase acidic protein E199K substitution in influenza A viruses on baloxavir susceptibility.

Impact of the polymerase acidic protein E199K substitution in influenza A viruses on baloxavir susceptibility.

An outbreak of influenza A(H1N1)pdm09 antigenic variants exhibiting cross-resistance to oseltamivir and peramivir in an elementary school in Japan, September 2024.

An outbreak of influenza A(H1N1)pdm09 antigenic variants exhibiting cross-resistance to oseltamivir and peramivir in an elementary school in Japan, September 2024.

Impact of COVID-19 on Respiratory Virus Infections in Children, Japan, 2018-2023.

Impact of COVID-19 on Respiratory Virus Infections in Children, Japan, 2018-2023.

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients.

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients.

Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023.

Monitoring Influenza C and D Viruses in Patients With Respiratory Diseases in Japan, January 2018 to March 2023.

A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023.

A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023.

Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.

Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.

Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses.

Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses.

Antiviral Susceptibilities of Avian Influenza A(H5), A(H7), and A(H9) Viruses Isolated in Japan.

Antiviral Susceptibilities of Avian Influenza A(H5), A(H7), and A(H9) Viruses Isolated in Japan.